Trial Profile
An Open-label, Multicenter, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NantPharma
- 01 Apr 2024 Status changed from suspended to withdrawn prior to enrolment.
- 15 Jun 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2024.
- 15 Jun 2020 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2024.